Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Solid Tumors: early-phase trial registry
70 of 145 indexed Advanced Solid Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #81 of 28,707 conditions by registered trial count.
145 US clinical trials · 70 currently recruiting · #81 of 28,707 conditions by registered trial count
Advanced Solid Tumors: 145 US clinical trials tracked, 70 recruiting.
Advanced Solid Tumors is the subject of 145 registered US clinical trials on ClinicalTrials.gov, 70 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 144 in Phase 1-2 (earlier-stage). The most active sponsor is Amgen, running 5 of these trials.
Enrollment posture brief
Registry condition advanced-solid-tumors
OPEN 70 | RECR 48% | LATE 1 | EARLY 144 | RANK #81 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Gynecologic Cancer (48% recruiting · 56 trials)
Advanced Solid Tumors lists 70 open slots (48% of 145 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Solid Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Solid Tumors is recruiting above its size-band peers.
70 of 145 indexed trials (48.3%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Advanced Solid Tumors trials is spread across many organizations.
Amgen accounts for 5 of 145 trials (3.4%). 100 distinct sponsors appear on at least one study for this condition label.
-
Typical Advanced Solid Tumors enrolment sits around 120 participants.
Median target enrolment is 120 among the 145 trials that report a genuine target (sentinel values excluded). 63 of those (43.4%) plan for fewer than 100 participants.
-
Advanced Solid Tumors research is mostly interventional.
145 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
145 total, page 1 of 3
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
American Society of Clinical Oncology
NCT02693535
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
Regeneron Pharmaceuticals
NCT04626635
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio
NCT05914116
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
Merck Sharp & Dohme
NCT05067283
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Revolution Medicines
NCT05379985
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Revolution Medicines
NCT06040541
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
AskGene Pharma
NCT05867420
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Revolution Medicines
NCT07349537
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NextCure
NCT06792552
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT06697197
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
Incyte Corporation
NCT05836324
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Revolution Medicines
NCT07397338
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Global Development
NCT05083481
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Marengo Therapeutics
NCT05592626
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
ModernaTX
NCT05533697
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors
Bristol-Myers Squibb
NCT06730750
SNV4818 in Participants With Advanced Solid Tumors
Pikavation Therapeutics
NCT06736704
A Study of BG-C477 in Participants With Advanced Solid Tumors
BeOne Medicines
NCT06596473
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
LigaChem Biosciences
NCT05941507
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Vividion Therapeutics
NCT06004245
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
Jacobio Pharmaceuticals Co.
NCT06973564
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics
NCT05954312
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Merck Sharp & Dohme
NCT06818643
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Gilead Sciences
NCT06167317
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co.
NCT06459973
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis
NCT06657222
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D
NCT06480552
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Regeneron Pharmaceuticals
NCT06413680
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
NCT06993844
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors
Vividion Therapeutics
NCT06804824
A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
NCT06544655
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Astellas Pharma Global Development
NCT05719558
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
OnKure
NCT06239467
A Study of JNJ-87890387 for Advanced Solid Tumors
Janssen Research & Development
NCT06178614
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics
NCT06835569
To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation
Abion
NCT05541822
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
Merck Sharp & Dohme
NCT05853367
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
Sun Pharma Advanced Research Company Limited
NCT07042100
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics
NCT07197554
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Ottimo Pharma Limited
NCT07266428
A Study of PHN-012 in Patients With Advanced Solid Tumors
Pheon Therapeutics
NCT07127874
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Eikon Therapeutics
NCT07262619
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co.
NCT06384352
A Study of PHST001 in Advanced Solid Tumors
Pheast Therapeutics
NCT06840886
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
Gilead Sciences
NCT06532565
A Study of ZW191 in Participants With Solid Tumors
Zymeworks BC
NCT06555744
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
EMD Serono Research & Development Institute
NCT07360314
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Eikon Therapeutics
NCT06907043
A Study of MGC028 in Participants With Advanced Solid Tumors
MacroGenics
NCT06723236
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Genmab
NCT07387068
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 137 |
| Phase 2 | 7 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Solid Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Solid Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Solid Tumors page
145 registered trials, 70 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 70 Advanced Solid Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Amgen sponsors the most Advanced Solid Tumors trials on record, review their full trial history before evaluating a specific study. See Amgen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Solid Tumors condition card totals 145 registered trials; most-linked intervention Pembrolizumab; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.